top of page
.png)
Eyes on Pharma
Check-out What Intel Caught our Eye
Eyes On the Evolving Pharma Landscape - Part 3
In Part 3 of our Series on how the pharma landscape is being reshaped - from the inside out - we have Eyes On where late-stage clinical execution is still cutting through uncertainty as de-risked assets redefine standards of care and company trajectories.
PharmaTell
Jan 152 min read
Eyes on Oncology, Anti-Virals, and Consumer Products
We've had our Eyes On recent data releases, commercial strategy updates, and some FDA updates. What caught your Eye last week?
Jana Chisholm
Jul 7, 20245 min read
bottom of page